Taysha Gene Therapies financials
$4.990.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — | — |
| Gross profit | $9.8M | $8.3M | $15.5M | $2.5M | — | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M | -$43.0M |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M | -$60.0M |
| Net margin | −1115.3% | −1071.6% | −722.1% | −6635.3% | — | — |
| Diluted EPS | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 |
| EBITDA | -$109.4M | -$85.4M | -$70.0M | -$123.5M | -$172.8M | -$43.0M |
| Operating cash flow | -$93.1M | -$81.2M | -$73.0M | -$92.6M | -$117.0M | -$30.7M |
| Free cash flow | -$93.8M | -$81.6M | -$80.4M | -$113.3M | -$132.3M | -$30.8M |
| Diluted shares | 319.7M | 250.1M | 116.1M | 44.0M | 37.7M | 17.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $50.1M | $43.9M | $40.5M | $38.0M | $37.2M | $0.00 |
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M | $7.6M |
| Shareholders' equity | $246.9M | $71.5M | $74.9M | $949.0K | $95.4M | $251.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology